Advertisement
Loading...

Upexi, Inc.

GRVINASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$4.95
$0.35(7.61%)
U.S. Market opens in 28h 22m

Upexi, Inc. Fundamental Analysis

Upexi, Inc. (GRVI) shows weak financial fundamentals with a PE ratio of -1.41, profit margin of -11.37%, and ROE of -2.54%. The company generates $0.0B in annual revenue with weak year-over-year growth of -67.77%.

Key Strengths

PEG Ratio0.00
Current Ratio1.72

Areas of Concern

ROE-2.54%
Operating Margin-10.92%
Cash Position1.07%
We analyze GRVI's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1100.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1100.1/100

We analyze GRVI's fundamental strength across five key dimensions:

Efficiency Score

Weak

GRVI struggles to generate sufficient returns from assets.

ROA > 10%
-1.15%

Valuation Score

Excellent

GRVI trades at attractive valuation levels.

PE < 25
-1.41
PEG Ratio < 2
0.00

Growth Score

Weak

GRVI faces weak or negative growth trends.

Revenue Growth > 5%
-67.77%
EPS Growth > 10%
-24.43%

Financial Health Score

Excellent

GRVI maintains a strong and stable balance sheet.

Debt/Equity < 1
-4.67
Current Ratio > 1
1.72

Profitability Score

Weak

GRVI struggles to sustain strong margins.

ROE > 15%
-253.94%
Net Margin ≥ 15%
-11.37%
Positive Free Cash Flow
No

Key Financial Metrics

Is GRVI Expensive or Cheap?

P/E Ratio

GRVI trades at -1.41 times earnings. This suggests potential undervaluation.

-1.41

PEG Ratio

When adjusting for growth, GRVI's PEG of 0.00 indicates potential undervaluation.

0.00

Price to Book

The market values Upexi, Inc. at -6.25 times its book value. This may indicate undervaluation.

-6.25

EV/EBITDA

Enterprise value stands at 0.67 times EBITDA. This is generally considered low.

0.67

How Well Does GRVI Make Money?

Net Profit Margin

For every $100 in sales, Upexi, Inc. keeps $-11.37 as profit after all expenses.

-11.37%

Operating Margin

Core operations generate -10.92 in profit for every $100 in revenue, before interest and taxes.

-10.92%

ROE

Management delivers $-2.54 in profit for every $100 of shareholder equity.

-2.54%

ROA

Upexi, Inc. generates $-1.15 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.15%

Following the Money - Real Cash Generation

Operating Cash Flow

Upexi, Inc. generates limited operating cash flow of $-6.70M, signaling weaker underlying cash strength.

$-6.70M

Free Cash Flow

Upexi, Inc. generates weak or negative free cash flow of $-6.55M, restricting financial flexibility.

$-6.55M

FCF Per Share

Each share generates $-0.36 in free cash annually.

$-0.36

FCF Yield

GRVI converts -26.85% of its market value into free cash.

-26.85%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-1.41

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.001

vs 25 benchmark

P/B Ratio

Price to book value ratio

-6.25

vs 25 benchmark

P/S Ratio

Price to sales ratio

4.40

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-4.67

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.72

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-2.54

vs 25 benchmark

ROA

Return on assets percentage

-1.15

vs 25 benchmark

ROCE

Return on capital employed

-1.70

vs 25 benchmark

How GRVI Stacks Against Its Sector Peers

MetricGRVI ValueSector AveragePerformance
P/E Ratio-1.4128.62 Better (Cheaper)
ROE-253.94%783.00% Weak
Net Margin-1137.43%-48181.00% (disorted) Weak
Debt/Equity-4.670.39 Strong (Low Leverage)
Current Ratio1.724.12 Neutral
ROA-114.80%-21914.00% (disorted) Weak

GRVI outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Upexi, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

16565.63%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-57134.38%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-5699.81%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ